|
1
|
Powell DJ Jr, Russell J, Nibu K, Li G,
Rhee E, Liao M, Goldstein M, Keane WM, Santoro M, Fusco A, et al:
The RET/PTC3 oncogene: Metastatic solid-type papillary carcinomas
in murine thyroids. Cancer Res. 58:5523–5528. 1998.PubMed/NCBI
|
|
2
|
Nikiforova MN, Kimura ET, Gandhi M,
Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G,
Fusco A, et al: BRAF mutations in thyroid tumors are restricted to
papillary carcinomas and anaplastic or poorly differentiated
carcinomas arising from papillary carcinomas. J Clin Endocrinol
Metab. 88:5399–5404. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hong DS, Cabanillas ME, Wheler J, Naing A,
Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El
Naggar AK, et al: Inhibition of the Ras/Raf/MEK/ERK and RET kinase
pathways with the combination of the multikinase inhibitor
sorafenib and the farnesyltransferase inhibitor tipifarnib in
medullary and differentiated thyroid malignancies. J Clin
Endocrinol Metab. 96:997–1005. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nikiforov YE and Nikiforova MN: Molecular
genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol.
7:569–580. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu H, Lu Y, Li Z and Wang Q: microRNA-133:
Expression, function and therapeutic potential in muscle diseases
and cancer. Curr Drug Targets. 15:817–828. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhi F, Wang Q, Deng D, Shao N, Wang R, Xue
L, Wang S, Xia X and Yang Y: MiR-181b-5p downregulates NOVA1 to
suppress proliferation, migration and invasion and promote
apoptosis in astrocytoma. PLoS One. 9:e1091242014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang X, Li M, Zuo K, Li D, Ye M, Ding L,
Cai H, Fu D, Fan Y and Lv Z: Upregulated miR-155 in papillary
thyroid carcinoma promotes tumor growth by targeting APC and
activating Wnt/β-catenin signaling. J Clin Endocrinol Metab.
98:E1305–E1313. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brest P, Lassalle S, Hofman V, Bordone O,
Gavric Tanga V, Bonnetaud C, Moreilhon C, Rios G, Santini J, Barbry
P, et al: MiR-129-5p is required for histone deacetylase
inhibitor-induced cell death in thyroid cancer cells. Endocr Relat
Cancer. 18:711–719. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Geraldo MV, Fuziwara CS, Friguglieti CU,
Costa RB, Kulcsar MA, Yamashita AS and Kimura ET: MicroRNAs
miR-146-5p and let-7f as prognostic tools for aggressive papillary
thyroid carcinoma: A case report. Arq Bras Endocrinol Metabol.
56:552–557. 2012. View Article : Google Scholar
|
|
11
|
Bou Kheir T, Futoma-Kazmierczak E,
Jacobsen A, Krogh A, Bardram L, Hother C, Grønbæk K, Federspiel B,
Lund AH and Friis-Hansen L: miR-449 inhibits cell proliferation and
is down-regulated in gastric cancer. Mol Cancer. 10:12011.
View Article : Google Scholar
|
|
12
|
Trupp M, Arenas E, Fainzilber M, Nilsson
AS, Sieber BA, Grigoriou M, Kilkenny C, Salazar-Grueso E, Pachnis
V, Arumäe U, et al: Functional receptor for GDNF encoded by the
c-ret proto-oncogene. Nature. 381:785–789. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gujral TS, van Veelen W, Richardson DS,
Myers SM, Meens JA, Acton DS, Duñach M, Elliott BE, Höppener JW and
Mulligan LM: A novel RET kinase-beta-catenin signaling pathway
contributes to tumorigenesis in thyroid carcinoma. Cancer Res.
68:1338–1346. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Marx SJ: Molecular genetics of multiple
endocrine neoplasia types 1 and 2. Nat Rev Cancer. 5:367–375. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Arighi E, Borrello MG and Sariola H: RET
tyrosine kinase signaling in development and cancer. Cytokine
Growth Factor Rev. 16:441–467. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hoppler S and Kavanagh CL: Wnt signalling:
Variety at the core. J Cell Sci. 120:385–393. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moon RT, Kohn AD, De Ferrari GV and Kaykas
A: WNT and beta-catenin signalling: Diseases and therapies. Nat Rev
Genet. 5:691–701. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Garcia-Rostan G, Camp RL, Herrero A,
Carcangiu ML, Rimm DL and Tallini G: Beta-catenin dysregulation in
thyroid neoplasms: Down-regulation, aberrant nuclear expression,
and CTNNB1 exon 3 mutations are markers for aggressive tumor
phenotypes and poor prognosis. Am J Pathol. 158:987–996. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gujral TS, van Veelen W, Richardson DS,
Myers SM, Meens JA, Acton DS, Duñach M, Elliott BE, Höppener JW and
Mulligan LM: A novel RET kinase-β-catenin signaling pathway
contributes to tumorigenesis in thyroid carcinoma. Cancer Res.
68:1338–1346. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu J, Ma L, Li C, Zhang Z, Yang G and
Zhang W: Tumor-targeting TRAIL expression mediated by miRNA
response elements suppressed growth of uveal melanoma cells. Mol
Oncol. 7:1043–1055. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ma L, Liu J, Liu L, Duan G, Wang Q, Xu Y,
Xia F, Shan J, Shen J, Yang Z, et al: Overexpression of the
transcription factor MEF2D in hepatocellular carcinoma sustains
malignant character by suppressing G2-M transition genes. Cancer
Res. 74:1452–1462. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gilles C, Polette M, Mestdagt M,
Nawrocki-Raby B, Ruggeri P, Birembaut P and Foidart JM:
Transactivation of vimentin by β-catenin in human breast cancer
cells. Cancer Res. 63:2658–2664. 2003.PubMed/NCBI
|
|
23
|
Luo W, Huang B, Li Z, Li H, Sun L, Zhang
Q, Qiu X and Wang E: MicroRNA-449a is downregulated in non-small
cell lung cancer and inhibits migration and invasion by targeting
c-Met. PLoS One. 8:e647592013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fang Y, Gu X, Li Z, Xiang J and Chen Z:
miR-449b inhibits the proliferation of SW1116 colon cancer stem
cells through downregulation of CCND1 and E2F3 expression. Oncol
Rep. 30:399–406. 2013.PubMed/NCBI
|
|
25
|
Yang X, Feng M, Jiang X, Wu Z, Li Z, Aau M
and Yu Q: miR-449a and miR-449b are direct transcriptional targets
of E2F1 and negatively regulate pRb-E2F1 activity through a
feedback loop by targeting CDK6 and CDC25A. Genes Dev.
23:2388–2393. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Buurman R, Gürlevik E, Schäffer V, Eilers
M, Sandbothe M, Kreipe H, Wilkens L, Schlegelberger B, Kühnel F and
Skawran B: Histone deacetylases activate hepatocyte growth factor
signaling by repressing microRNA-449 in hepatocellular carcinoma
cells. Gastroenterology. 143:811–820.e15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takeuchi K, Soda M, Togashi Y, Suzuki R,
Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, et
al: RET, ROS1 and ALK fusions in lung cancer. Nat Med. 18:378–381.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Melillo RM, Castellone MD, Guarino V, De
Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R,
Kruhoffer M, et al: The RET/PTC-RAS-BRAF linear signaling cascade
mediates the motile and mitogenic phenotype of thyroid cancer
cells. J Clin Invest. 126:16032016. View
Article : Google Scholar :
|
|
29
|
Lin C, Lu W, Ren Z, Tang Y, Zhang C, Yang
R, Chen Y, Cao W, Wang L, Wang X, et al: Elevated RET expression
enhances EGFR activation and mediates EGFR inhibitor resistance in
head and neck squamous cell carcinoma. Cancer Lett. 377:1–10. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bano G and Hodgson S: Diagnosis and
management of hereditary thyroid cancer. Recent Results Cancer Res.
205:29–44. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Drilon A, Bergagnini I, Delasos L, Sabari
J, Woo KM, Plodkowski A, Wang L, Hellmann MD, Joubert P, Sima CS,
et al: Clinical outcomes with pemetrexed-based systemic therapies
in RET-rearranged lung cancers. Ann Oncol. 27:1286–1291. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bauman TM, Vezina CM, Ricke EA, Halberg
RB, Huang W, Peterson RE and Ricke WA: Expression and
colocalization of β-catenin and lymphoid enhancing factor-1 in
prostate cancer progression. Hum Pathol. 51:124–133. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lan L, Deng W, Chen H, Huo L, Deng L,
Zhang G and Luo Y: Nuclear translocation of β-catenin represses
membrane localization of NIS in human thyroid cancer cells.
Zhonghua Yi Xue Za Zhi. 96:891–896. 2016.(In Chinese). PubMed/NCBI
|
|
34
|
Li T, Zhong J, Dong X, Xiu P, Wang F, Wei
H, Wang X, Xu Z, Liu F, Sun X, et al: Meloxicam suppresses
hepatocellular carcinoma cell proliferation and migration by
targeting COX-2/PGE2-regulated activation of the β-catenin
signaling pathway. Oncol Rep. 35:3614–3622. 2016.PubMed/NCBI
|
|
35
|
Lombardi AP, Pisolato R, Vicente CM,
Lazari MF, Lucas TF and Porto CS: Estrogen receptor beta (ERβ)
mediates expression of β-catenin and proliferation in prostate
cancer cell line PC-3. Mol Cell Endocrinol. 430:12–24. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen Q, Zheng PS and Yang WT:
EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin
signaling-dependent cell expansion in cervical carcinoma.
Oncotarget. Apr 15–2016.(Epub ahead of print). View Article : Google Scholar
|
